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SUMMARY The use oftumour associated antigens in the diagnosis of serous effusions was studied in
76 patients with benign and 200 patients with malignant disease. Tissue polypeptide antigen (TPA), a
fetoprotein, and CA 125 were found to be of little value. At cut off points of 3 ng/ml, 10 U/ml, and 30
U/ml, respectively, carcinoembryonic antigen (CEA), biliary glycoprotein I (BGP I), and CA 19-9
discriminated between benign and malignant serous effusions with a sensitivity of between 24% and
67%. The immunocytochemical staining for these markers resulted in malignant cells being detected
in 18% to 33% of cases. Various combinations of conventional cytological examination, effusion
fluid tumour marker determination, and immunocytochemical analysis identified malignant cells in
serous effusions in up to 72% of cases; conventional cytology alone detected tumour cells in only
30%.
We describe an investigation into the use of tumour
markers for the discrimination of benign and malig-
nant serous effusions. Although conventional
cytology, the classic diagnostic tool for ascitic and
pleural effusions, detects malignant cells with a
specificity of almost 100%, its sensitivity is unsatisfac-
tory. Various investigators have reported that routine
cytological examinations recognise malignant cells in
serous effusions with a sensitivity of between only
28 and 60%.'" In our series positive cytological
results were noted in only 42 of 139 (30%) serous
effusions from patients with histologically confirmed
malignancies.
Tumour associated antigens may be used in the
diagnosis of serous effusions in two ways: firstly, the
antigen titres may be determined in the effusion fluid
by methods used for the examination of serum;
secondly, the antigens may be detected immunocyto-
chemically in cells from the effusion.
For carcinoembryonic antigen (CEA), tissue
polypeptide antigen (TPA), biliary glycoprotein I
(BGP I), and CA 19-9 and CA 125, we tested the
ability of both methods to discriminate between
benign and malignant causes of serous effusions and,
in addition, the value ofdetermining concentrations of
aL fetoprotein (AFP) in serous effusion fluid. Serum
concentrations of CEA and CA 125 were also deter-
mined in some of the patients.
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Patients and samples
One hundred and seventy six pleural effusions, 97
ascitic effusions, and three abdominal drainage fluid
specimens were collected from 276 patients aged
between 18 and 83 years. Two hundred samples came
from patients who had been documented as having
malignant disease on the basis of clinical evaluation
together with radiological studies, surgical biopsy, or
necropsy. In all but eight cases the origin of the
neoplasm was clearly established. In 76 patients none
of the examinations showed evidence of malignant
disease. The diagnoses of all patients are listed in table
1. Necropsy was performed in 32 patients between one
week and one year after collection of serous effusion
fluid samples. In all but two malignant cases (n = 24)
tumour was found in the pleura or peritoneum.
CONVENTIONAL CYTOLOGY
Conventional cytological diagnoses were made by
three independent observers without knowledge of the
clinical diagnoses from cytospin preparations stained
by the Pappenheim technique and periodic acid Schiff
reagent. The findings were recorded as "positive",
"negative", or "suspicious" for the presence of malig-
nant cells.
IMMUNOCYTOCHEMICAL STAINING ANTIBODIES
Indirect immunocytochemical staining using perox-
idase or alkaline phosphatase conjugated antibodies
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Table 1 Diagnosis in 273 patients with ascitic andpleural
effusions
Ascitic Pleural
Benign effusions:
Cirrhosis of liver 27 1
Congestive heart failure 3 5
Alcoholic hepatitis I
Ovarian fibroma I
Osteomyelofibrosis I
Chiari disease I
Tuberculosis 9
Pneumonia 6
Viral pleuritis 5
Connective tissue disease 2
Amyloidosis I
Mediastinal tumour, complete
remission after radiation 4
Bronchial tumour, complete
remission after pneumonectomy 2
Bronchial adenoma I
Pancreatitis I
Perforated gastric ulcer I
Rupture of the oesophagus I
Malignant effusions:
Carcinomas
Gastrointestinal 20 7
Ovary 15 7
Breast 14 51
Kidney 1 5
Non-small cell lung cancer 5
Small cell lung cancer 5
Various 2 1
Unknown primary 4 4
Lymphomas/leukaemias 4 21
Mesotheliomas 8
Sarcomas 2 4
Melanomas 2
Teratomas I
was performed by our own modification of standard
techniques, as previously described.78 For immuno-
cytochemical studies we used the following antibodies:
rabbit polyclonal antibodies to CEA, absorbed
with human lung and colon mucosa extract, as
previously described;9 murine monoclonal antibodies
to CEA (CEA-84, from Hofmann-LaRoche, Basel,
Switzerland) and two of our own monoclonal
antibodies; rabbit polyclonal antibodies to TPA
(Mallinckrodt Diagnostica, Dietzenbach, West
Germany); rabbit polyclonal antibodies to BGP I-like
antigen, prepared as previously described;'" mono-
clonal antibody OC 125 to the antigen CA 125 (kindly
provided by Dr RC Bast, Boston, USA); monoclonal
antibody to CA 19-9 (Isotopen Diagnostik, Dreieich,
West Germany); and immunoglobulins from a murine
myeloma cell line as controls.
EFFUSION FLUID TUMOUR MARKER ASSAY
After centrifugation at 3000 rpm for 20 minutes, the
samples were frozen at - 20°C and stored for up to six
months before assay. CEA, oa fetoprotein, and BGP I
concentrations were determined by a double antibody
radioimmunoassay, as previously described,9"0 TPA
by a commercial radioimmunoassay, and CA 19-9 and
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CA 125 by commercial immunoradiometric assays
(Mallinckrodt Diagnostica, Dietzenbach, West
Germany) according to the manufacturer's instruc-
tions. CEA and CA 125 concentrations were also
determined in samples collected within three days after
or before the puncture of the effusion in some of the
patients.
The Mann-Whitney U test was used to assess the
significance of differences in tumour marker values
among patients with benign and malignant diseases.
The X2 test was used to assess the correlation oftumour
marker concentrations in serous effusion fluid and
positive immunocytochemical findings. For compar-
ison of serous effusion fluid and serum tumour marker
values, the linear regression and the rank correlation
coefficient (rj) were determined. Optimal cut off limits
for the discrimination of benign and malignant serous
effusions were set with the use of receiver operating
characteristic (ROC) diagrams. All statistical tests
were performed as described by Sachs."
Results
CONVENTIONAL CYTOLOGY
Malignant cells were recognised morphologically in 36
of 106 (34%) specimens from patients with carcin-
omas, three of 19 lymphomas/leukaemias, one of six
sarcomas, one of seven mesotheliomas, and in one
melanoma. In all other malignant cases the diagnosis
of "suspicious" or "negative" was recorded; in 50
samples from benign diseases the diagnosis was
",negative". In 87 patients serous effusion fluid only
had been examined and conventional cytological
diagnoses were not available.
IMMUNOCYTOCHEMICAL STAINING
In the control specimens eosinophilic and basophilic
granulocytes were stained by the immunoperoxidase
technique. None of the CEA antibodies stained
mesothelial cells, lymphocytes, or macrophages. With
the polyclonal anti-CEA and our own monoclonal
antibodies to CEA, all granulocytes were positive with
the peroxidase and the alkaline phosphatase method.
Stained granulocytes could be easily distinguished
from other positive cells by their morphology. CEA-84
did not stain any cells in benign effusions. Effusions
containing positive cells apart from granulocytes were
found in the same way with all CEA antibodies,
mainly in patients with carcinomas of the breast,
gastrointestinal tract, and non-small cell lung cancer
(table 2). By their morphology and by comparison
with Pappenheim stained slides, all CEA positive cells
other than polymorphs seemed to be carcinoma cells
(fig 1). Rabbit anti-CEA was used for most examina-
tions as it gave the most intense staining.
In almost all specimens a diffuse or droplet-like
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Table 2 Detection (%) oftumour cells by cytology, inmunocytochemistry, and combination ofboth methods in 136 patients
Positivefindings
Immunocytochemistry
Cytology and
(n= ) Cytology CEA BGP I CA 19-9 immunocytochemistry
Carcinomas 87 34 27 18 33 66
Breast 32 19 31 12 6 56
Ovary 15 80 0 13 46 87
Gastrointestinal 15 40 47 13 60 73
Non-small cell lung cancer 14 29 57 35 57 64
Small cell lung cancer 2 50 0 0 50 50
Kidney 4 0 0 0 0 0
Various/unknown primary 5 20 20 60 40 60
Mesotheliomas 5 20 0 0 0 20
Lymphomas, leukaemias 14 2 0 0 0 14
Sarcomas 3 0 0 0 0 0
Benign diseases 27 0 0 0 0 0
staining of the cytoplasm of mesothelial cells was
noted with TPA. When carcinoma cells could be
distinguished from mesothelial cells by morphological
criteria, they were found to be positive. Lymphocytes,
granulocytes, and macrophages were not stained.
Granulocytes were positive in all cases with anti-
BGP I. Apart from granulocytes, cells stained by anti-
BGP I were found only in carcinomatous effusions,
and these positive cells were characterised by their
morphology as carcinoma cells (fig 2). A droplet-like
staining of the cytoplasm of mesothelia was also
observed in some cases. Effusions containing meso-
thelial or carcinoma cells positive for BGP I were
found in patients with breast and gastrointestinal
carcinomas and non-small cell lung cancer. In two
cases of ovarian carcinoma, tumour cells were weakly
stained.
In 11 of 14 serous effusions of ovarian carcinoma,
tumour cells were labelled by OC 125. Positive cells,
however, were also found in benign effusions and
could be defined by their morphology as small clusters
of proliferating mesothelia (fig 3), and occasionally as
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Fig 1 Pleural effusion in non-small cell lung cancer,
polyclonal anti-CEA, immunoperoxidase method: staining of
carcinoma cell cluster.
Fig 2 Pleural effusion in breast carcinoma, anti-BGP I,
immunoperoxidase method: staining ofa single carcinoma
cell.
Mezger, Permanetter, Gerbes, Wilmanns, Lamerz
4i.,
*A?l
Fig 3 Ascitic effusion in ovarianfibroma, OC 125,
immunoperoxidase method: droplet-like staining of
mesothelial cells.
single mesothelial cells. CA 125 positive cell clusters
and single cells were also observed in carcinomatous
effusions. These cells could not be positively identified
as tumour cells or mesothelia in all cases. Granu-
locytes, lymphocytes, and macrophages were not
stained. CA 19-9 positive cells were found only in
patients with breast, gastrointestinal, and ovarian
carcinomas and non-small cell lung cancer (table 2).
MostCA 19-9 positive cells were characterised by their
morphology as carcinoma cells. In some cases a
droplet-like staining of the cytoplasm of mesothelial
cells was noted (fig 4).
IMMUNOCYTOCHEMICAL STAINING INDICATIVE
OF MALIGNANCY
According to Ghosh, effusions containing more than
five cells positive for CEA, BGP I, or CA 19-9 apart
from granulocytes were classified as "positive for
malignancy".' Table 2 shows the distribution of
positive findings according to tumour type compared
with those obtained by conventional cytological
diagnoses. Positive immunocytochemical findings
were noted in 20 of 76 (26%) cases in which the
conventional cytological diagnoses were reported as
"negative" or "suspicious" (n = 16 with anti-CEA,
n = 11 with anti-BGP I, n = 8 with anti-CA 19-9). In
87 carcinomas tumour cells were identified in 30 (34%)
serous effusions by conventional cytology alone.
When immunocytochemical staining for only one
Fig 4 Pleural effusion in breast carcinoma anti-CA 19-9,
immunoperoxidase method: droplet-like staining of
mesothelial cells.
marker was used in addition to conventional cytology,
carcinoma cells were detected in 53% (CEA), 47%
(BGP I), and 43% (CA 19-9). The combined use of
conventional cytology and immunocytochemical
staining for CEA, BGP I, and CA 19-9 detected
malignancy in 58 of 87 (66%) of carcinomas.
EFFUSION FLUID TUMOUR MARKERS
In 103 serous effusions all six tumour associated
antigens were determined; CEA concentrations were
also available in a further 83 samples. Figs 5 and 6
show the data for CEA, BGP I, TPA, CA 19-9 and CA
125. An AFP concentration above 15 ng/ml was found
in only five ascitic fluids (four carcinomas, one liver
cirrhosis). We found significant differences between
the concentrations in benign and malignant disease:
CEA (p < 0-001); BGP I (p < 0-05 and p < 0-02,
respectively) in ascitic and pleural effusions; TPA
(p < 0 03) and CA 19-9 (p < 0-02) in ascitic effusions.
Using ROC diagrams (figs 7 and 8), we chose a cut off
limit for each marker at values corresponding to the
most significant discrimination of benign and malig-
nant disorders: CEA, 3 ng/ml; BGP I, 10 U/ml; TPA,
2000 U/ml; CA 19-9, 30 U/ml. Our cut off values for
serous effusion fluid were near or equal to the recom-
mended normal serum limits for CEA, BGP I, and CA
19-9. They were about 20 times higher for TPA and
unobtainable for CA 125.
The sensitivity, specificity, and positive and negative
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predictive values for each marker and for the combina-
tion of two and three markers for these cut off limits
are listed in table 3. The prevalence of increased
concentration depended on the site of the primary
lesion (table 4). In cases of benign disease with
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increased concentrations of serous effusion fluid
tumour markers, CEA concentrations were raised in
bronchial adenoma, pulmonary fibrosis after surgery,
and after radiation of a thymoma with complete
recovery over five years, in tuberculous and viral
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Fig 5 Effusionfluid tumour marker concentrations in ascitic effusions. For
CEA, 18 benign and 33 malignant cases;for BGP I, CA 19-9, TPA, and
CA 125, 12 benign and 25 malignant cases.
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Fig 6 Effusionfluid tumour marker concentrations in pleural effusions. For
CEA, 30 benign and 96 malignant cases;for BGP I, CA 19-9, TPA, and
CA 125, 15 benign and 51 malignant cases.
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pleuritis, sepsis, cirrhosis, congestive heart failure (3-6
to 9 ng/ml) and rupture ofthe oesophagus (390 ng/ml).
BGP I was raised in bronchial adenoma (52 U/1),
tuberculosis (11 U/1), congestive heart failure (16 U/1),
and liver cirrhosis (23 U/1). In three drainage fluid
specimens collected after laparotomy because of per-
forated duodenal and gastric ulcers or gall bladder,
CEA concentrations of 18, 12, and 15 ng/ml, respec-
tively, were obtained.
Specificity
c
n(A
0.0 0.2 0.4 0.6 0.8 1.0
FP
Fig 7 ROC diagrams derivedftom data shown infig S
(ascitic effusions). * = CEA, A = BGP I, M = CA 19-9,
0 = TPA, * = cut off, FP = false positive, FN = false
negative result.
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Fig 8 ROC diagrams derivedfrom data shown infig 6
(pleural effusions). * = CEA, A = BGP I, = CA 19-9,
0 = TPA, * = cut off, FP = false positive, FN = false
negative result.
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CORRELATION OF IMMUNOCYTOCHEMICAL
FINDINGS AND EFFUSION FLUID TUMOUR
MARKER VALUES IN MALIGNANT CASES
For CEA, data from immunocytochemically stained
slides and serous effusion fluid concentrations were
available in 70 cases of malignancy. Values above
the cut off limit were found in 13 of 15 immuno-
cytochemically positive effusions. In 56 immuno-
cytochemically negative serous effusions, diagnos-
tically positive effusion fluid concentrations were
found in 13 cases. The combined use of both methods
improved the sensitivity in these cases from 21% and
37% to 40%. For BGP I, the corresponding values
were: 12 immunocytochemically positive cases with six
raised effusion fluid values and 19 immunocyto-
chemically negative cases with eight raised effusion
fluid values. This increased the detection rate from
39% and45% to 65%. ForCA 19-9 the corresponding
values were: 11 immunocytochemically positive cases
with eight positive effusion fluid values, 25 immuno-
cytochemically negative cases with five diagnostically
negative effusion fluid values. This improved the
sensitivity from 31% (immunocytochemistry) and
36% (effusion fluid) to 44% (combined). There was a
significant correlation between the immunocyto-
chemical detection of tumour marker positive cells in
serous effusions and effusion fluid values of the same
marker indicative for malignancy (X2 test, p < 0-0 1).
Table 3 Percentage sensitivity, specificity, positive and
negative predictive value ofCEA, BGP I, TPA, and CA 19-9
compared with prevalence ofmalignant disease in 51 ascitic
and 126 pleural effusions (CEA) and all markers in 37 ascitic
and 66 pleural effusions
Predictive value:
Prevalence Sensitivity Spec#ficity Positive Negative
CEA* As 65 51 96 96 51
PI 76 48 78 87 32
BGP It As 68 48 92 92 46
P1 78 35 82 85 30
TPA$ As 68 61 85 90 50
P1 78 67 41 74 30
CA 19-9§ As 68 52 100 100 50
P1 78 24 100 100 31
CEA + As 68 64 92 95 61
BGPI P1 78 65 82 88 45
CEA + As 68 56 100 100 52
CA 19-9 P1 78 55 94 96 42
BGPI + As 68 72 92 95 61
CA 19-9 P1 78 47 82 88 35
As 68 72 92 95 61
All markersPl 78 65 82 91 45
*3 ng/ml CEA, t1O U/ml BGP 1, T2000 U/ml TPA,
§ 30 U/ml CA 19-9
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Table 4 Effusionfluid tumour marker concentrations indicativefor malignancy
No (%) effusions No ofeffusions Percentage positive Percentage positive Percentage positive
testedfor CEA > testedfor all with CEA > with BGPI > ith CA 19-9 >
3ng/ml three markers 3 ng/ml 10 U/ml 30 U/ml
Carcinomas 117 (50) 57 63 35 49
Breast 49 (57) 23 61 22 17
Ovary 12 (17) 4 25 50 25
Gastrointestinal 17 (82) 13 92 54 100
Non-small cell lung cancer 17 (76) 8 89 56 100
Small cell lung cancer 1(100) 0
Kidney 6(0) 3 0 0 0
Various/unknown primary 5 (20) 5 20 20 50
Mesotheliomas 6 (17) 2 0 0 0
Lymphomas, leukaemias 18 (17) 10 10 50 50
Sarcomas 7 (17) 4 0 75 75
Teratomas 1 (0) 1 0 100 100
Melanoma 1 (100) 0
Benign diseases 49 (6) 39 3 10 0
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Fig 9 Correlation ofserous effusionfluid and serum CEA in
99 malignant cases. Regression line: serum CEA (ng/ml) =
0 171 x serous effusionfluid CEA + 16 4 (ng/ml).
CORRELATION BETWEEN SEROUS EFFUSION FLUID
AND SERUM CONCENTRATIONS OF CEA AND CA
125
In 40 of 49 benign cases serum CEA concentrations
were below 3 ng/ml: the highest value was 7-3 ng/ml.
Fig 9 charts the serum and serous effusion fluid CEA
concentrations in 99 patients with malignant disease.
In these patients the mean serum: serous effusion fluid
CEA ratio was 13:1. In 11 malignant cases with
positive immunocytochemical CEA staining the ratio
was 46:5; in 46 malignant cases with negative
immunocytochemical CEA staining the ratio was 11:9.
There was a significant linear correlation between
serum and serous effusion fluid CEA values
(rs = 0-77, p < 0-01). The regression line formula is:
serum CEA (ng/ml) = 0 171 x effusion fluid CEA + 16 4 (ng/ml)
CA 125 was determined simultaneously in sera and
serous effusion fluid from 26 patients with benign and
44 patients with malignant disease. There was no
significant difference between both groups either for
serum or for effusion fluid values. Range and median
serum CA 125 concentrations were 22-1837 U/I and
256 U/l in benign cases and 21-4323 U/I and 342 U/i in
malignant cases. The corresponding effusion fluid
values were 113-3410 U/I and 512 U/l in benign
disease, and 99 to > 40000 U/l and 812 U/I in
malignant disease. There was a significant correlation
of serum and effusion fluid CA 125 values in patients
with benign as well as in those with malignant disease
(p < 0001).
Discussion
In only about a third of the malignant serous effusions
of our series were tumour cells detected by cytology
alone, and this agrees with the findings of previous
publications. There are three possible causes of the
unsatisfactory sensitivity of conventional cytology.
The effusion might be caused by a concomitant benign
disease. In our series, however, in almost all malignant
cases tumour was present in the pleura or the periton-
eum at necropsy. Furthermore, in spite of disease in
the serous membranes none or only a few tumour cells
may have been released into the effusion fluid. The
difficulty in identifying tumour cells arises from the
polymorphism of proliferating mesothelial cells in
benign as well as in malignant disorders of the pleura
or the peritoneum. These proliferating mesothelial
cells must not be confused with tumour cells, and a
positive diagnosis must be made with caution.
Numerous simple laboratory tests have been asses-
sed for their capacity to differentiate benign from
malignant effusions, such as the content of lactic acid
dehydrogenase,'2 '5 glucose concentration,'2"8 protein
concentration,'2 13 '9 lactic acid content,'4 162' cell
count,'6 17 pH values,'6 1 serum ascites ratio of
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albumin,22 and red cell count.23 For some of these tests,
the first optimistic reports were not confirmed in other
studies. Other tests were applicable only in sterile
effusions and gave false positive results in infected
patients. The most promising examinations of this
type are the determination of cholesterol24 and
fibronectin,2526 although both tests seem to be useful
mainly in ascitic fluid and less so in pleural effusions.
Although until now none of the so-called tumour
associated antigens could be shown to be specific for
malignant disease, their determination seems to be a
more direct approach to establishing the nature of the
underlying disease. Numerous reports have documen-
ted the usefulness of determining CEA in serous
effusion fluid as well as its immunocytochemical
demonstration.
In our study the staining of granulocytes by
antibodies to CEA and BGP I seems to have been
caused by a cross reaction with non-specific cross
reacting antigen (NCA).2728 It did not impair the value
of these antibodies as granulocytes could easily be
recognised by their morphology and could not be
confused with tumour cells. Our data confirm that a
positive reaction for CEA excludes a malignant
mesothelioma or a non-neoplastic proliferation of
serosa cells.2"33 The diversity of the immunocyto-
chemical staining for CEA in different tumour types is
consistent with serological and immunohistochemical
studies about the distribution of this antigen.9 1116
TPA occurs closely related to the intermediate
filaments of epithelial and carcinoma cells.3738 As in
mesothelia the cytoskeleton proteins of epithelial and
mesenchymal cells can be shown,39 and it is not
surprising that we also found TPA in mesothelia.
OC 125 recognises a determinant (CA 125) which is
associated with epithelial ovarian neoplasms.4"2 As
anti-CEA seldom stains ovarian carcinoma cells in
serous effusions, OC 125 might fill a gap in effusion
immunocytochemistry. Indeed, OC 125 reacted with
tumour cells in almost all samples from ovarian
carcinoma. On the other hand, our results confirm the
findings of Kabawat, who reported that CA 125 also
occurs in proliferating mesothelia.43
BGP I is antigenetically related to CEA and seems
to occur mostly in normal gastrointestinal organs and
gastrointestinal carcinomas.'044 The results of our
immunocytochemical staining support the assump-
tion that BGP I is a tumour associated antigen
distributed differently from CEA. Like CEA, it occurs
in carcinomas of the gastrointestinal tract and the
lung, but unlike CEA it was found in breast carcin-
omas only rarely. Additionally, staining of ovarian
carcinoma cells, though weak, was observed.
Like BGP I, CA 19-9 occurs mostly in benign and
malignant gastrointestinal tissues.354"7 In our study
both immunocytochemically positive specimens as
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well as raised serous effusion fluid values were found
mostly in gastrointestinal and ovarian carcinomas and
only in a few breast carcinomas and non-small cell
lung cancer.
The misdiagnosis of a neoplasm in patients with a
benign disease could lead to very far reaching
sequelae. Normally occurring antigens in serous mem-
branes or in benign diseases are therefore not suitable
for diagnostic tests. TPA and CA 125, therefore, do
not seem to be suitable for the immunocytochemical
diagnosis of tumours in serous effusions. CA 148 and
epithelial membrane antigen549 have been described as
occurring only in malignant effusions. Other inves-
tigators, however, detected the antigens in mesothelia
in benign specimens as well.3033 Antisera to keratin,33
a fetoprotein,32 pregnancy specific ,B 1-glycoprotein32
and placental alkaline phosphatase32 were found to
stain only carcinoma cells, but provided little
additional information when compared with CEA.
The distribution ofdifferent molecular weight keratins
showed that mesothelial and adenocarcinoma cells
had a different staining pattern.5' The monoclonal
antibody B 72-3 was developed by immunising mice
with a membrane enriched fraction of a human
carcinoma. Ninetyfive per cent staining of adenocar-
cinoma cells in serous effusions and the absence of
mesothelial cell staining has recently been reported for
this antibody.52 To our knowledge, the remarkable
sensitivity of this monoclonal antibody has so far not
been confirmed by other investigators. Furthermore,
the monoclonal antibodies AUA I,' Ca 2, and Ca 353
have been described as specific for malignant cells in
serous effusions.
In our study the occurrence of cells positive for
CEA, CA 19-9, or BGP I was specific for the presence
ofa carcinoma. Not all positive cells, however, seem to
be carcinoma cells. Obviously, material derived from a
tumour and phagocytosed by mesothelia had been
stained in some cases. The morphology of the cells in
immunocytochemically stained slides and the fact that
positive cells were found mostly in effusions diagnosed
as positive by conventional cytology, indicate that
positively stained cells in most cases were carcinoma
cells. Positively stained cells, however, were also found
in 26% of serous effusions from patients with malig-
nant disease which had been diagnosed cytologically
as "negative" or "suspicious". Therefore, immuno-
cytochemical staining for these antigens seems to be
helpful in diagnosis, although even with anti-CEA, the
most sensitive of the three antibodies, tumour cells
could be detected in only 24% of carcinoma cases.
Nevertheless, compared with conventional cytology
alone, the additional use of immunocytochemistry
raised the sensitivity of the detection of a carcinoma
from 32% to 63%. In effusions selected for the
presence of tumour cells, a staining of adenocarcin-
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oma cells by anti-CEA has been reported in 44% to
80% of cases.3"33 Using antibodies to Ca 1 and
HMFG-2 in addition to anti-CEA, Ghosh et al
identified carcinoma cells in 15 of 53 cytologically
negative effusions.' These figures cannot be directly
compared with our results, as in our study a con-
secutive, unselected series was examined. Like CEA,
BGP I and CA 19-9 are restricted to certain types of
carcinomas. Therefore the antigenic pattern of the
tumour cells might give valuable information about
the site of the primary lesion. Thus in spite of the
considerable effort necessary for this technique,
immunocytochemical staining for all three antigens
should be considered as part of the diagnostic
procedure in cases with serous effusions of unknown
origin.
Effusion fluid tumour markers can be determined by
techniques used for the examination of serum and
should be available more readily than immunocyto-
chemical techniques. On the other hand, this method
does not directly identify malignant cells and is thus
more likely to give false positive results.
Stanford et al failed to show a significant difference
between CEA concentrations in pleural effusions in
patients with mesothelioma, inflammatory lung dis-
ease, and bronchial carcinoma.54 In 15 reports on the
determination of CEA in serous effusion fluid
summarised by Faravelli in 1984,2 and in other
studies,3 cut off values between 2 5 and 40 ng/ml
were recommended for the discrimination of benign
and malignant effusions, resulting in a specificity for
malignancy of between 85% and 100% and a sen-
sitivity of between 27% and 88%. This diversity seems
to reflect both the different ranges ofnormal values for
the tests applied as well as a different selection of
patients. Furthermore, it emphasises that cut off
values established for normal serum specimens cannot
be applied to those of serous effusions without further
investigation.
Our data confirm that high CEA values in serous
effusion fluid in patients with benign disease are found
more commonly in inflammatory disease."' Interes-
tingly, high CEA concentrations also occurred in
drainage and effusion fluid specimens from patients
with perforations of gastrointestinal organs. CEA
occurs in high concentrations in gastrointestinal
mucus.61
In agreement with Braun et al,62 we found a
significant linear correlation between serum and
serous effusion fluid CEA concentrations. In a con-
siderable number of patients, however, a serous
effusion fluid CEA value indicative ofmalignancy was
combined with a normal serum CEA concentration
and thus was able to provide diagnostically useful
additional information. The mean value of serous
effusion fluid: serum CEA ratios of 13:1 found in this
study in patients with various malignant diseases was
similar to those reported by Nystrom et al63 and Asseo
et al.57 In agreement with observations by Di Stefano
et al,' in patients with breast cancer the ratio was
significantly lower. A high serous effusion fluid: serum
tumour marker ratio could be indicative for a tumour
mass in the pleural or peritoneal cavity, and a low ratio
could indicate effusions caused only indirectly by the
tumour. This assumption was supported by most of
our results, as in effusions with a positive immuno-
cytochemical CEA staining (indicative for neoplastic
disease in the serous membranes) a much higher serous
effusion fluid: serum CEA ratio was found than in
immunocytochemically negative cases. In a few
effusions containing tumour marker positive cells,
however, low serous effusion fluid and serum tumour
marker concentrations were found. This might be
explained by reduced or absent secretion of these
antigens by the tumour.
The formation of the antigens by mesothelial cells
seems to explain the prevalence of high concentrations
of CA 125 and TPA in serous effusion fluid. The close
statistical correlation between CA 125 in serous
effusion fluid and serum concentrations and the
surprisingly high incidence of raised CA 125 serum
concentrations in benign disorders affecting the serous
membranes (also observed by lanucci; abstract
presented at International Symposium on Mono-
clonal Antibodies, Florence, Italy, 1984) and Berg-
mann et al67 seem to indicate that in some cases the
production of the antigen in mesothelium might be the
cause of raised serum concentrations.
High CA 125 concentrations in effusion fluid can
also occur in benign disease and are therefore not a
recommendation for the diagnostic use of this test. To
obtain sufficient specificity our cut off value for TPA
(2000 U/1) in serous effusion fluid had to be set much
higher than the discriminatory limit recommended for
serum TPA (80-120 U/1).6"' This resulted in com-
paratively low sensitivity and positive predictive
values. For similar reasons, BGP I concentrations in
pleural effusions seem to be less helpful in diagnosis.
In contrast, determination ofCA 19-9 in ascitic and
in pleural effusions and that of BGP I in ascitic
effusions are specific and sensitive enough to become
valuable tools in diagnosis, although these tests are
similar to determination of CEA in serous effusion
fluid and are positive in only about 1/3 to 1/2 of
malignant cases. As the single antigens exhibited
raised concentrations in different patient groups
(depending partly on the site ofthe primary lesion), the
combination of two or three markers increased the
sensitivity considerably. For some combinations,
however, the specificity was too low for clinical use.
In agreement with the reports of Martinez-Vea et
al8 we found raised AFP concentrations in effusion
641
642 Mezger, Permanetter, Gerbes, Wilmanns, Lamerz
fluid only rarely. This reflects the narrow range of
tumours which usually express this antigen. Couch3
found that human ,B chorionic gonadotrophin gave a
specificity for malignancy of 96% and a sensitivity of
36% at a cut offof 10 mIU/ml. High concentrations of
a 1 -acidylglycoprotein in serous effusion fluid are not
specific for malignancy, but in a series of 50 patients
values below 39 ng/ml were found only in benign
disease.58
Until now tumour markers have not discriminated
between benign and malignant aetiologies in serous
effusions with satisfying sensitivity. On careful
examination of benign specimens, however, cut off
values can be derived for some antigens which are
useful in identifying a tumour, especially an adeno-
carcinoma as the cause of the effusion. To date, the
best antigen is CEA. As shown by our study, both the
immunocytochemical staining for CA 19-9 and BGP I
as well as the determination of the concentrations of
these antigens in serous effusion fluid provide valuable
additional information about the cause of pleural and
peritoneal effusions. Depending on the circumstances,
we recommend a combination of these methods to
increase diagnostic accuracy.
We thank MsM Darsow, G Wochinger, A Brandt and
E Segura for excellent technical assistance. Drs W
Klaubert, KE Haiussinger, and F Cujnik generously
provided effusion and serum specimens.
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